18 studies found for: brca | Open Studies | United States, Massachusetts
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer
Cisplatin vs Paclitaxel for Triple Neg BRCA
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children
|9||Not yet recruiting||
Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.
Eribulin in HER2 Negative Metastatic BrCa
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
The Cancer of the Pancreas Screening-5 CAPS5)Study
A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
† Indicates status has not been verified in more than two years